{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "INGN",
  "name": "Inogen, Inc",
  "url": "https://frontierpicks.com/dossiers/INGN/",
  "json_url": "https://frontierpicks.com/dossiers/INGN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Inogen's shares are more likely to lag the S&P 500 after its first report as a pure oxygen-concentrator maker showed revenue down 2.4% and a lower outlook, leaving a new CEO's $20 million cost program to carry the case. The fourth-quarter report, expected around February 2027, shows whether losses narrow.",
  "invalidation_trigger": "A daily close above $6.38, above both the 50-day and 200-day moving averages and the post-report closes, would show the shares leading the S&P 500 and prove this call wrong; so would fourth-quarter 2026 revenue above the $68 million top of the guide.",
  "catalyst_date": null,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "Inogen Announces Third Quarter 2026 Financial Results",
      "url": "https://www.stocktitan.net/news/INGN/inogen-announces-third-quarter-2026-financial-y80chgwbhihx.html",
      "date": "2026-11-05"
    },
    {
      "title": "Inogen (INGN) Q3 2026 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2026/11/06/inogen-ingn-q3-2026-earnings-call-transcript/",
      "date": "2026-11-06"
    },
    {
      "title": "Finviz",
      "url": "https://finviz.com/news/418119/inogens-reset-quarter-us-growth-returns-but-an-international-reversal-and-lower-guidance-hit-a-stock-priced-for-better-news",
      "date": "2026-11-05"
    },
    {
      "title": "Inogen Announces Third Quarter 2026 Financial Results",
      "url": "https://www.morningstar.com/news/business-wire/20261105640263/inogen-announces-third-quarter-2026-financial-results",
      "date": "2026-11-05"
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue from continuing operations was $77.2 million, down 2.4% from $79.1 million and down 3.2% in constant currency.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Third-quarter 2026 US sales were $42.2 million, up 3.8%, and international sales were $34.9 million, down 9.0%.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Guidance from continuing operations is fourth-quarter revenue of $65 million–$68 million, full-year 2026 revenue of $298 million–$301 million and a full-year adjusted loss of $7 million–$8 million.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The loss from continuing operations was $14.8 million against $3.6 million a year earlier, including a $10.6 million goodwill impairment; adjusted gross margin was 44.2% against 45.9% a year earlier.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Cash, marketable securities and restricted cash totaled $97.7 million with no debt; third-quarter operating cash flow was about negative $4.5 million.",
      "source": "Inogen Q3 2026 results release and earnings call",
      "as_of": "2026-09-30"
    },
    {
      "claim": "The US oxygen rental business sale to Rotech Healthcare closed with estimated cash consideration of up to $24.8 million, expected in the first half of 2027.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-02"
    },
    {
      "claim": "A cost program targets about $20 million of annual savings by the end of 2027, with the first $10 million due before the end of 2026.",
      "source": "Inogen Q3 2026 earnings call",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Andy Reding, the chief operating officer, was appointed President and CEO, succeeding Kevin Smith.",
      "source": "Inogen Q3 2026 results release",
      "as_of": "2026-11-05"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-09",
              "restated": null,
              "value_musd": 77.2,
              "yoy_pct": -2.4
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-07",
              "restated": null,
              "value_musd": 95.1,
              "yoy_pct": 3
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "value_musd": 85.1,
              "yoy_pct": 3.4
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": "2026-11-09",
              "value_musd": 79.1,
              "yoy_pct": -11
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "value_musd": 92.3,
              "yoy_pct": 4
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-09",
              "restated": null,
              "pct": 44.1
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-07",
              "restated": null,
              "pct": 45.5
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "pct": 44.5
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": "2026-11-09",
              "pct": 45.7
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "pct": 44.8
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-09",
              "restated": null,
              "pct": -20.2
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-07",
              "restated": null,
              "pct": -5.4
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "pct": -11
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-06",
              "restated": "2026-11-09",
              "pct": -6.9
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "pct": -6.6
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": -14.6
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "four_quarters_end": "2026-09-30",
          "value_musd": -16.2,
          "four_quarters_musd": -35.5
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "first_end": "2025-12-31",
          "value_musd": -9.2
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "first_end": "2025-12-31",
          "value_musd": 2.2
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "first_end": "2025-12-31",
          "value_musd": -11.3
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "base_end": "2025-09-30",
          "pct": -2.3
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 96.8
        },
        "debt": {
          "status": "none reported"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 96.8,
          "note": "no debt reported"
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 2.6,
          "yoy_pct": -36.5
        },
        "backlog": {
          "status": "ok",
          "end": "2025-12-31",
          "filed": "2026-02-27",
          "value_musd": 1.1,
          "yoy_pct": -33
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 48.6
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 29
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-09",
          "value_musd": 157
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-29",
          "basis_filed": "2026-11-09",
          "value_musd": 148
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-29",
          "basis_filed": "2026-11-09",
          "value_musd": 51.1,
          "note": "no debt reported"
        },
        "ev_sales": {
          "status": "not available"
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-29",
          "basis_filed": "2026-11-09",
          "multiple": 0.9
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-29",
          "basis_filed": "2026-11-09",
          "pct": -7.7
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 5.89,
      "days_to_cover": 4.1,
      "change_pct": 3.9
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 142518.9,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\nInogen's shares are more likely to lag the S&P 500 than to beat it over the next three months. Its first report as a pure oxygen-concentrator maker, on 2026-11-05, showed revenue down 2.4% and a lower outlook. The company also replaced its chief executive officer (CEO) that day. The case now rests on a $20 million cost program and $97.7 million of cash. The fourth-quarter report, expected around February 2027, shows whether losses narrow and international sales recover.\n\nThird-quarter revenue from continuing operations was $77.2 million, against $79.1 million a year earlier, and fell 3.2% in constant currency (company release, 2026-11-05). The company guided fourth-quarter revenue to $65 million–$68 million and full-year 2026 revenue to $298 million–$301 million. It replaced an adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) target of about $4 million with a full-year adjusted loss from continuing operations of $7 million–$8 million (Earnings Whispers, 2026-11-05). The new CEO, Andy Reding, said on the call: \"These results are not where they need to be, and we are taking action to improve them.\"\n\nThe market has repriced the report. The shares closed at $5.75 on 2026-11-11, below the $7.22 close of 2026-11-04, the last session before the results, and the 3-month change is −1.0%. That price assumes the lower guide holds. Results that beat it would test the call.\n\n## Bull Case\n- **US sales returned to growth.** US sales were $42.2 million in the third quarter of 2026, up 3.8% year on year (company release, 2026-11-05). Management said on the 2026-11-05 call that this was the first growth since the fourth quarter of 2024, and that it expects US growth to speed up in the fourth quarter.\n- **The rental sale has closed.** The sale of the US oxygen rental business to Rotech Healthcare closed on 2026-11-02, with estimated cash consideration of up to $24.8 million, expected in the first half of 2027 (company release, 2026-11-05). It comes with a long-term supply agreement for Inogen's concentrators.\n- **Costs are coming down.** A program begun in the fourth quarter of 2026 targets about $20 million of annual savings by the end of 2027, with the first $10 million due before the end of 2026 (2026-11-05 call). Management expects more than $40 million of annual operating expense savings against the pre-sale run rate, once the divestiture is counted.\n- **Cash with no debt.** Cash, marketable securities and restricted cash totaled $97.7 million on 2026-09-30, with no debt outstanding (company release, 2026-11-05).\n- **The company is buying back stock.** Inogen repurchased 1,786,850 shares for $11.2 million in 2026 through the third-quarter report, and raised its authorization by $15 million to $45 million (company release, 2026-11-05).\n\n## Bear Case\n- **International sales reversed sharply.** International sales were $34.9 million in the third quarter of 2026, down 9.0% and down 10.4% in constant currency, after a rise of about 15% in the second quarter (company release, 2026-11-05; Earnings Whispers, 2026-11-05). Management blamed softer capital spending and inventory management at large European customers and expects that to continue into the fourth quarter.\n- **The outlook keeps moving lower.** The $65 million–$68 million fourth-quarter guide sits below the $77.2 million just reported (company release, 2026-11-05). The full-year guide had been $366 million–$373 million at the start of 2026 and $355 million–$361 million in August, both before the rental business was split out (Earnings Whispers, 2026-11-05).\n- **Revenue missed estimates.** Revenue of $77.2 million compared with a $92.25 million estimate (Benzinga, 2026-11-05). Those estimates appear to include rental revenue, which was $11.6 million in the second quarter, and that amount does not close the whole gap.\n- **Losses are wider and margin is lower.** The loss from continuing operations under generally accepted accounting principles was $14.8 million, against $3.6 million a year earlier, including a $10.6 million goodwill impairment (company release, 2026-11-05). Adjusted gross margin fell to 44.2%, from 45.6% in the second quarter and 45.9% a year earlier.\n- **Cash is shrinking.** The cash total fell to $97.7 million on 2026-09-30 from $106.8 million on 2026-06-30. Third-quarter operating cash flow was about negative $4.5 million, after positive $2.9 million in the second quarter, driven by a working-capital build (company releases; Earnings Whispers, 2026-11-05).\n- **Leadership and yardsticks both changed.** Reding, who joined as chief operating officer in July, succeeded Kevin Smith as CEO on 2026-11-05. The company moved its main profit measure to adjusted net earnings without giving a dated profit target (2026-11-05 call).\n\n## Setup & Price Structure\nThe shares closed at $7.22 on 2026-11-04, $6.77 on 2026-11-05 and $6.03 on 2026-11-06, as the report and the lower guide were absorbed (adjusted daily closes). Earnings Whispers noted on 2026-11-05 that the shares had risen 22.5% between the August report and the $7.22 close, so the post-report drop gave back most of that run.\n\nThe last close was $5.75 on 2026-11-11. That sits below the 50-day moving average of $5.99 and the 200-day moving average of $6.24, both as of 2026-11-11. A recovery above both averages would be the first price sign that the market is looking past the guide cut.\n\nThe 52-week high is $7.67, set intraday on 2026-04-28, and the last close is 25.0% below it. The 52-week closing low is $5.09, from 2026-09-23, just before the divestiture announcement. The 3-month change is −1.0%, measured from the $5.81 close of 2026-08-13.\n\n## Catalyst Calendar\n\n- **~2026-12-31 (est.):** Deadline for completing the first $10 million of the cost program. It is the first check on whether the new CEO's savings arrive on the schedule given on the 2026-11-05 call.\n- **~2027-02-25 (est.):** Fourth-quarter 2026 report; the company has not announced the date. It tests the $65 million–$68 million revenue guide and the $7 million–$8 million adjusted loss guide, and shows whether international sales have recovered.\n- **~2027-06-30 (est.):** Latest expected receipt of the up to $24.8 million rental sale proceeds, which the company places in the first half of 2027. The final amount and timing show how much cash the divestiture adds to the $97.7 million reported for 2026-09-30.\n\n## What Would Change Our Mind\n\nA daily close above $6.38, above both the 50-day and 200-day moving averages and the post-report closes, would show the shares leading the S&P 500 and prove this call wrong; so would fourth-quarter 2026 revenue above the $68 million top of the guide.\n\n## Correlation Notes\nRecent moves in the shares trace to company events: the 2026-09-30 divestiture announcement and the 2026-11-05 report. The outside drivers named by management are capital spending and inventory decisions at large European customers. Currency also matters: it narrowed the third-quarter revenue decline to 2.4% from 3.2% in constant currency. Rotech's demand is a further link, through the long-term supply agreement that came with the 2026-11-02 closing.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T03:53:46+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}